ALK and non-small cell lung carcinoma: In the case of NSCLC, much of the recent research has focused on epidermal growth factor receptor (EGFR) mutations and aberrant fusions of the anaplastic lymphoma kinase (ALK) or c-ros oncogene 1 (ROS1) genes [6, 7].